About Index Trending news
Analyze
Pricing
Intellia Therapeutics

Intellia Therapeutics

Intellia Therapeutics

Treating genetic disease at the cutting edge: Intellia Therapeutics is a CRISPR/Cas9 focused biotechnology company.

Elsewhere

Alexa global traffic share

Twitter followers

Latest funding Show all
IPO
$108,000,000
Venture capital (Series B)
$70,000,000
Employees

Team size

10+
Locations
HQ
Xconomy

CRISPR Drug Maker Intellia Therapeutics Sells $108M In IPO Shares

Science Health
Xconomy

With CRISPR in Humans On The Horizon, Will the Public Back Intellia?

Science
Xconomy

CRISPR Developer Intellia Deals With Regeneron, Jumps Into IPO Queue

Science